A CRITICAL REVIEW ON COLON TARGETED DRUG DELIVERY SYSTEMS FOR MANAGEMENT OF INFLAMMATORY BOWEL DISEASE

被引:0
作者
Jaiswal, Meenakshi [1 ]
Lanjhiyana, S. K. [1 ]
机构
[1] Guru Ghasidas Vishwavidyalaya, SLT Inst Pharmaceut Sci, Dept Pharmaceut, Bilaspur 495009, Chhattisgarh, India
关键词
Colon-specific drug delivery; Colonic disease; Inflammatory disease; Gastrointestinal tract; Evaluation of drugs targeting colon; THERAPY; CANCER;
D O I
10.13040/IJPSR.0975-8232.10(3).985-92
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inflammatory bowel disease (IBD) refers to the inflammation of the colon and small intestine of the body, in which Crohn's disease and ulcerative colitis are the principal types of IBD. This article covers most of the information related to a drug delivery system for treatment regarding intestinal diseases more emphasized to inflammatory bowel diseases. Currently, using delivery systems for targeting drugs to colon are osmotic drug delivery system, chronotropic system, pulsinicap system, multiparticulate system, port system, COLAL-Pred system, gas empowered drug delivery system have included in this article. An approach for targeting drugs to the colon is a probiotic approach has also included in this article. These delivery systems are being used to improve the bioavailability of the poorly absorbed drug. The purpose of this review article is to study about techniques employed in colon targeting for the prevention and treatment of IBD.
引用
收藏
页码:985 / 992
页数:8
相关论文
共 42 条
[1]   Management of malignant colon polyps: Current status and controversies [J].
Aarons, Cary B. ;
Shanmugan, Skandan ;
Bleier, Joshua I. S. .
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (43) :16178-16183
[2]   Role of Probiotics in health improvement, infection control and disease treatment and management [J].
Amara, A. A. ;
Shibl, A. .
SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (02) :107-114
[3]   Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches [J].
Amidon, Seth ;
Brown, Jack E. ;
Dave, Vivek S. .
AAPS PHARMSCITECH, 2015, 16 (04) :731-741
[4]  
Badoni A., 2012, The pharma innovation, V1, P32
[5]  
Bhagwat RR, 2013, INT J PHARM SCI RES, V4, P970
[6]  
Bostanci O, 2014, EUR REV MED PHARMACO, V18, P2533
[7]  
Devi V Kusum, 2010, Pharmacogn Rev, V4, P27, DOI 10.4103/0973-7847.65322
[8]   Granuloma-positive Crohn's disease [J].
Freeman, Hugh J. .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 21 (09) :583-587
[9]  
Gandhi B, 2013, Int J Pharm Chem Sci, V2, P1620
[10]   Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics [J].
Katsanos, Konstantinos H. ;
Papadakis, Konstantinos A. .
GUT AND LIVER, 2017, 11 (04) :455-463